Revvity (RVTY) Projected to Post Earnings on Monday

Revvity (NYSE:RVTY - Get Free Report) is expected to post its Q2 2025 quarterly earnings results before the market opens on Monday, July 28th. Analysts expect Revvity to post earnings of $1.14 per share and revenue of $711.26 million for the quarter. Revvity has set its FY 2025 guidance at 4.900-5.000 EPS.

Revvity (NYSE:RVTY - Get Free Report) last released its quarterly earnings results on Monday, April 28th. The company reported $1.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.96 by $0.05. Revvity had a return on equity of 7.73% and a net margin of 10.35%. The firm had revenue of $664.76 million for the quarter, compared to the consensus estimate of $662.30 million. During the same quarter last year, the business posted $0.98 EPS. The firm's quarterly revenue was up 2.3% compared to the same quarter last year. On average, analysts expect Revvity to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Revvity Stock Performance

Revvity stock traded down $2.36 during mid-day trading on Monday, reaching $90.90. 1,351,207 shares of the company were exchanged, compared to its average volume of 979,713. Revvity has a twelve month low of $87.70 and a twelve month high of $129.50. The firm's 50-day simple moving average is $95.10 and its two-hundred day simple moving average is $103.86. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.99 and a current ratio of 3.58. The firm has a market cap of $10.71 billion, a PE ratio of 38.68, a price-to-earnings-growth ratio of 2.35 and a beta of 0.98.

Revvity Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, August 8th. Stockholders of record on Friday, July 18th will be issued a $0.07 dividend. The ex-dividend date of this dividend is Friday, July 18th. This represents a $0.28 annualized dividend and a dividend yield of 0.31%. Revvity's dividend payout ratio is currently 11.91%.

Institutional Investors Weigh In On Revvity

Hedge funds have recently bought and sold shares of the stock. Focus Partners Wealth increased its stake in Revvity by 13.0% in the first quarter. Focus Partners Wealth now owns 7,028 shares of the company's stock valued at $744,000 after acquiring an additional 811 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in Revvity by 45.5% in the first quarter. Goldman Sachs Group Inc. now owns 607,104 shares of the company's stock valued at $64,232,000 after acquiring an additional 189,871 shares during the last quarter. Millennium Management LLC boosted its position in Revvity by 102.0% in the first quarter. Millennium Management LLC now owns 69,401 shares of the company's stock valued at $7,343,000 after buying an additional 35,048 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Revvity by 6.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 11,776 shares of the company's stock valued at $1,246,000 after buying an additional 744 shares in the last quarter. Finally, AQR Capital Management LLC boosted its position in Revvity by 5.2% in the first quarter. AQR Capital Management LLC now owns 8,449 shares of the company's stock valued at $883,000 after buying an additional 420 shares in the last quarter. 86.65% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

RVTY has been the subject of a number of recent analyst reports. Raymond James Financial reaffirmed an "outperform" rating and issued a $120.00 price objective (down previously from $145.00) on shares of Revvity in a research report on Tuesday, April 29th. Wells Fargo & Company lowered their price target on Revvity from $130.00 to $102.00 and set an "equal weight" rating for the company in a research report on Thursday, April 17th. Evercore ISI lowered their price target on Revvity from $116.00 to $115.00 and set an "outperform" rating for the company in a research report on Tuesday, July 8th. Wall Street Zen downgraded Revvity from a "buy" rating to a "hold" rating in a research report on Friday. Finally, JPMorgan Chase & Co. lowered their price target on Revvity from $120.00 to $100.00 and set a "neutral" rating for the company in a research report on Tuesday, April 29th. Five investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $123.07.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.